Related Experiment Video
Updated: May 28, 2026
Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation
Published on: July 6, 2019
Ulinastatin protects pulmonary tissues from lipopolysaccharide-induced injury as an immunomodulator
Chengjin Gao1, Rongrong Li, Sheng Wang
1Emergency Department and Surgical Intensive Care Unit, Shanghai 10th People's Hospital, Tongji University School of Medicine, Shanghai, China.
Background:
Organ protection is a routine therapy in patients with severe trauma, infection, and even multiple organ dysfunction syndrome. Appropriate inflammatory response benefits organ function with sepsis. Our aim was to verify the immunoregulatory effects of Ulinastatin (UTI) on lipopolysaccharide (LPS) administrated mice.
Methods:
C57BL/6J mice were subjected to an intraperitoneal injection of LPS and were randomly divided into a LPS control (L group) and an UTI-treated group (U group). Bone marrow-derived dendritic cells (DCs) were prepared from mouse femur bone marrow, and CD40, CD80, CD86, or MHC class II as DC markers were analyzed. The expression of spleen HLA-DR was detected by immunohistochemistry analysis. The alterations of Toll-like receptor 4-MyD88 signal pathway of DCs and pulmonary tissues were also determined. Selectins and adhesion molecules in lungs and serum were detected. The lung injury degree was represented as wet to dry ratios and alveolar thickness.
Results:
After LPS administration, the expression of bone marrow-derived DC marker was increased, showing a mature state, while the mature process could be stepped down by UTI. The spleen HLA-DR expression and the activation degree of Toll-like receptor 4-MyD88 signal pathway also demonstrated the immunoregulatory effects of UTI, which could effectively protect the pulmonary tissues from LPS-induced injury.
Conclusions:
Our results demonstrated that UTI reduced LPS-induced pulmonary injury. The mechanism of its action might involve the immunoregulation and the mitigation of excessive inflammatory reaction.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.